D uring the past decade, composite tissue allografts have inaugurated a new era in human transplantation. Allografts of the knee joint, 1 one hand, 2 the larynx, 3 both hands, 4 the abdominal wall, 5 and even the penis 6 have been successively reported. Most were per formed in patients with severe defects of nonvital parts of the body that could not be repaired with satisfactory functional and aesthetic results by con ventional surgery.
We previously reported the initial results 7 of a partial face transplantation that we performed in a woman who was disfigured by a severe dog bite and in whom conventional reconstruction was considered a poor option. Previous experiments in animals 8 had demonstrated the feasibility of face transplantation, but it had not been per formed in humans. Challenges included surgical considerations (determination of how to achieve the best aesthetic and functional results), immu nologic questions (identification of a suitable im munosuppressive protocol for preventing and re versing rejection of a composite graft that included the skin), and psychological considerations (as sessment of a person's ability to live with a face that is neither her own nor the donor's).
A report published soon after the graft was performed 7 described in detail the anatomic con sequences of the dog bite, preparation of the pa tient for the graft, and the surgical technique used, as well as the initial immunosuppression proto col and the patient's clinical evolution. The pres ent report focuses on the followup and clinical evolution during the first 18 months after trans plantation.
PAT IEN T A ND ME THODS

Patient
The recipient, a 38yearold woman, had been se verely bitten by her dog on May 28, 2005, resulting in amputation of her distal nose, her upper and lower lips, her entire chin, and the adjacent parts of her right and left cheeks. The face graft was performed on November 27, 2005, in Amiens, France. The donor, a braindead 46yearold wom an, and the recipient had the same blood group (O+) and shared five HLA antigens.
The approval of the local Protection of Per sons Committee, the French Agency for Health Safety, and the French Biomedicine Agency was obtained, and the patient signed a detailed in formedconsent form before undergoing trans plantation. The patient was evaluated preopera tively by three psychiatrists, including one whom she had seen regularly before undergoing trans plantation and two others who were involved in the care of recipients of hand transplants; these three psychiatrists also assessed her psychologi cal status after transplantation. The patient was transferred to Edouard Herriot Hospital in Lyon on November 30 for 6 weeks and was followed thereafter both in Amiens and in Lyon.
Surgical procedure
The procedure has previously been described in detail 7 and is shown schematically in Figure 1 . In addition to the face transplant, a conventional ra dial forearm flap was recovered from the donor for transplantation in the recipient's left submam mary fold and was used as a sentinel graft for skin biopsies to limit damage to the grafted face.
The immunosuppressive induction protocol in cluded intravenous antithymocyte globulin (Thy moglobulin, Genzyme) for 10 days, oral tacroli mus (target trough levels, 10 to 15 ng per milliliter throughout the first month), mycophenolate mo fetil (2 g per day), and prednisone (250 mg on day 1, 100 mg on day 2, and 60 mg per day through day 12, followed by a gradual taper). Medications were also given for prophylaxis of cytomegalovi rus infection and Pneumocystis jiroveci pneumonia. 7
Hematopoietic Stem-cell transplantation
Before surgery, bone marrow was collected from the donor's iliac crests. After 1724 ml of bone marrow had been harvested, 2.43×10 10 nucleated cells (4.64×10 8 per kilogram of body weight), 0.42×10 6 CD34+ cells per kilogram, and 7×10 4 granulocyte-macrophage colonyforming units (CFUGM) per kilogram were obtained. The bone marrow cells were stored in two equal portions in nitrogen gas.
In consistency with the Miami protocol used in cotransplantation of renal and bone marrow cells, 9 half of the bone marrow cells were infused into the recipient on days 4 and 11 after face allo transplantation. The number of viable infused CD34+ cells was 0.12×10 6 per kilogram on day 4 and 0.10×10 6 per kilogram on day 11; the num ber of infused CFUGM was 2×10 4 per kilogram on day 4 and 4×10 4 per kilogram on day 11. Chi merism was assessed on whole blood and on CD3+ and CD56+ cells at days 8, 14, 26, 39, 53, 69, 88, 124, 174, 330 , and 545 after transplanta tion, and on total and purified CD34+ bone mar row cells at days 14, 26, 53, 90, 174, 370, and 545 . Chimerism was determined by realtime quanti tative polymerase chain reaction (RQPCR) 10 with the use of TaqMan technology and an ABI 7700 Sequence Detector (Applera). The lower limit of the assay was 0.1%. Microchimerism was defined by the presence of 1% donor cells or less.
Extracorporeal photochemotherapy was initiat ed in late August 2006. It was performed, as de scribed elsewhere, 11 twice a week for 4 weeks, once a week for 8 weeks, once every 2 weeks for 2 months, and then once every 4 weeks for the duration of the 18month followup period.
Mucosa and skin biopsies of the cheek and the sentinel skin graft were performed at the time of rejection episodes and systematically every week for 1 month, monthly for 4 months, and every 6 months thereafter. To minimize the risk of scarring, only a small number of biopsies were performed on the face graft itself, and these were done only to evaluate rejection episodes. Ef fector T cells were isolated from sentinel skin graft biopsy specimens and cultured for 2 weeks with 20 IU of human interleukin2 per milliliter. Cytotoxicity was measured by the standard chro miumrelease assay. 51 Crlabeled type B EpsteinBarr virus lymphoblastoid cell lines generated from the donor, the recipient, or a thirdparty healthy blood donor who was fully mismatched with both the donor and the recipient were used as targets.
Physical therapy was started 48 hours after surgery and was performed twice daily for the first 4 months and once daily thereafter. The re habilitation program involved training in passive and active facial exercises, which were mainly fo cused on the restoration of lip movement and mouth occlusion. Psychological support was provided once daily during the first 4 postoperative weeks, twice weekly for the next 4 months, and then once a month or at the patient's request.
R e sult s
Functional results
The patient was able to eat and drink almost nor mally by the end of the first postoperative week, although leakage of her drinks from her mouth was sometimes observed; this disappeared com pletely by 12 months. At 8 months, she was oper ated on for an unexplained stenosis of the duct of Steno, and the outcome was favorable.
As assessed by repeated Semmes-Weinstein tests (light touch sensation studied by using static monofilaments), sensory discrimination was recovered quickly ( Fig. 2A) . Sensory discrimina tion was present on the lateral part of the upper lip and the lateral area of the chin and lower lip on both sides after 10 weeks and thereafter in volved the whole skin surface of the face trans plant, as well as the grafted oral mucosa. Heat and cold sensation was nearly normal at 4 months and normal at 6 months over the entire graft (Fig. 2B) . No contact hyperesthesia was observed.
Motor recovery was slower than sensory recov ery. The patient had some ability to move the upper lip by the 12th postoperative week. Motion of the lower lip recovered progressively from the fourth postoperative month. Since the third month after transplantation, improvement of lip closure has greatly facilitated the pronunciation of pho nemes such as P and B (see Supplementary Ap pendix 1, available with the full text of this article at www.nejm.org, for a video demonstrating the patient's facialmuscle function). Complete labial contact was present at 6 months ( Fig. 3A and 3B ). Endobuccal pressure (assessed with the use of an endobuccal balloon connected to a pressure mon itor) increased progressively, reflecting improved cheekmuscle strength. Contractions of the chin muscles and the nose pyramidal muscles were present at 12 months. Phonation and mastication continued to improve, with normal mobilization of the food bolus at 6 months. The smile, which was incomplete at 4 months, remained asymmet ric up to the 10th postoperative month but was nearly normal at 14 months and normal at 18 months. These functional improvements are re flected in the emotional expressions on the pa tient's face, such as when she has feelings of joy or sadness.
Immunologic outcome
Two episodes of acute rejection occurred on days 18 and 214 posttransplantation. Clinically, they were characterized by the gradual development of erythema and edema on the oral mucosa and on the skin of the face and the sentinel flap (Fig. 4) . Rejection was confirmed by biopsies of the skin of the face and the sentinel flap, which disclosed dermal edema, a predominantly lymphocytic in flammatorycell infiltrate of variable density, epi thelial (epidermis or mucous membrane) intra cellular edema, lymphocyte exocytosis, basalcell vacuolization, and keratinocyte apoptosis. Moder ate perivascularcell infiltration was also seen in the grafted derma. 12 These lesions were graded as 1 or 2 (mild and moderate rejection, respec tively), according to the classification established for acute rejection of composite tissue. 13 Immu nohistochemical studies showed that the lympho cytes were predominantly CD4+ cells, with a few CD8+ cells (data not shown). In support of these results, specific donordirected cytotoxic activity was observed in T cells isolated from the skin of the sentinel graft on days 36 and 214, but not in those isolated on day 76 (Fig. 5) , when clinical and histopathological signs of the first rejection had disappeared.
The first rejection episode was initially treat ed by increases in the doses of oral prednisone, tacrolimus, and mycophenolate mofetil, as well as clobetasol ointment and prednisone mouth washes. Subsequently, three 1000mg boluses of methylprednisolone were administered intrave nously, resulting in reversal of the rejection. The mucosa, the graft, and the sentinel flap returned to normal clinically and pathologically by day 45. 7 The second rejection episode was effectively treated by three 750mg boluses of methylpred nisolone administered intravenously every other day, combined with prednisone mouthwashes and local applications of clobetasol and tacrolimus ointments. Doses of oral corticosteroids were subsequently increased to 50 mg daily (1 mg per kilogram of body weight per day for 10 days) and progressively tapered to 5 mg daily over 8 weeks. The tacrolimus and mycophenolate mofetil doses remained unmodified.
Extracorporeal photochemotherapy was start ed 2 months after the second rejection episode in an effort to reduce the risk of further episodes of acute rejection, and this therapy has been well tolerated. Since September 2006, the appearance of the facial skin, the sentinel skin, and the oral graft mucosa has been normal. No graftversus host disease (GVHD) has developed.
Post-transplantation chimerism
Of the many assessments for microchimerism, only one suggested that microchimerism was present. This assessment occurred 2 months af ter transplantation, when RQPCR study showed 0.1% donor cells among the CD34+enriched population of bone marrow cells.
Infectious complications
Two infectious complications occurred. On day 185, a type 1 human herpes simplex virus infec tion of the lips was confirmed by virologic test ing and was treated effectively with oral valacy clovir and topical acyclovir cream. A few days after reversal of the second rejection episode, mollus cum contagiosum due to poxvirus appeared over the cheeks on both the allograft and the patient's own skin and was treated by curettage.
Other post-transplantation complications
When the patient was on the initial immunosup pressive regimen, she had a progressive decrease in renal function: inulin clearance was 90 ml per minute per 1.73 m 2 of bodysurface area before the graft and decreased to 59 and 43 ml per min ute per 1.73 m 2 at 6 and 12 months, respectively. The serum creatinine levels were 0.6, 0.9, and 1.5 mg per deciliter (53, 80, and 133 μmol per li ter) at baseline, 6 months, and 12 months, respec tively. There was no proteinuria. Renal failure was thought to be attributable to tacrolimus, although trough levels ranged from 8 to 10 ng per millili ter and never exceeded 15 ng per milliliter. Siro limus was introduced 11 months after transplan tation with a plan to gradually taper tacrolimus and preclude the nephrotoxicity of calcineurin inhibitors.
Five weeks later, when the tacrolimus and sirolimus trough levels were 4.9 and 3.3 ng per milliliter, respectively, moderate thrombotic mi croangiopathy developed, characterized by throm bocytopenia (platelet count, 100,000 per cubic millimeter), hemolytic anemia (hemoglobin level, 7.9 g per deciliter) with fragmented erythrocytes, acute renal failure (creatinine increased to 2.2 mg per deciliter [194 μmol per liter]), and hyperten sion. Tacrolimus and sirolimus were stopped, and fresh frozen plasma was infused for 4 days, com bined with a high dose of intravenous immune globulin. Thrombotic microangiopathy resolved within 8 days, and sirolimus was reintroduced 1 week later, when serum creatinine had dimin Figure 6 shows the patient's face before her inju ries, 1 year after transplantation, and 18 months after transplantation. The patient has not under gone formal psychological testing. By the end of the 12th postoperative week, the patient was ca pable of facing the outside world and gradually resumed a normal social life. The progressive re turn of expressiveness correlated well with psy chological acceptance of the foreign graft. At pres ent, the patient says she is not afraid of walking in the street or meeting people at a party, and she is very satisfied with the aesthetic and functional results.
Dis cus sion
At followup 18 months after face transplantation, the patient is doing well in terms of function of the transplant, social functioning, and her overall condition. Recovery of sensation (although sub normal) at 6 months and of lip mobility at 6 months contributed to the return of an almost normal appearance, and the patient is very satisfied with the results of the transplant. Despite the presence of only one HLADR mis match between the patient and the donor and the potent induction of immunosuppression, two episodes of rejection occurred; the second may have been triggered by the preceding herpesvirus infection. In contrast to reported rejections after hand transplantation, which were controlled by a moderate increase in the dose of prednisone and by local application of tacrolimus and corti costeroid creams, 14 boluses of injected cortico steroid were necessary to reverse acute skin rejec tion. Macroscopic changes of the oral mucosa (erythema and edema) appeared 2 days before the first skinrejection episode, suggesting that mu cosal rejection may appear before skin rejection.
Biopsies of the sentinel skin flap and donor oral mucosa were useful during the entire 18month followup period for the diagnosis of rejection. The macroscopic features of the sentinel flap cor responded well to those of the facial graft, and the pathologic patterns of rejection were similar when skinbiopsy specimens from both sites were com pared. This synchronicity should be confirmed in other patients before sentinelflap biopsies are used as a reliable marker of face rejection.
Concern about the possibility of irreversible skin rejection led us to use hematopoietic stem cell infusions. The role of donor hematopoietic stem cells in inducing tolerance of transplanted organs is uncertain. Nevertheless, the clinical re sults of previous kidney, pancreas, liver, and heart transplantations that included donor bone mar row infusions 9,15-18 have suggested a decrease in the risk of chronic rejection and longer graft survival, without specific complications connect ed with the procedure. In the cadaveric donor, bone marrow cells have been recovered from the iliac crest; the number of nucleated cells we col lected was considered adequate on the basis of reports of tandem bone marrow and kidney trans plantation from living, related donors. 19 How ever, despite the absence of apparent problems during harvesting, cryopreservation, and thaw ing, the numbers of CFUGM and viable CD34+ cells for both grafts were smaller than usually observed.
During the 18month followup, microchime rism was demonstrated in only one evaluation of the bone marrow. The relationship between mi crochimerism and tolerance is still controver sial. 20, 21 Immunoregulatory effects of donor bone marrow cells on the allogeneic cellular immune response have been shown. 22 The longterm pres ence of regulatory T lymphocytes after transplan tation was shown in a patient of ours who has the oldest hand allograft. 23 It is uncertain wheth er microchimerism due to the bone marrow trans planted with the hand allograft was necessary to induce this regulatory effect and whether a small number of hematopoietic stem cells ("nanochi merism" or "cryptochimerism") can play a role in "educating" T lymphocyte cell lines at the cen tral or peripheral level. Extracorporeal photoche motherapy, an alternative treatment for cortico steroidresistant GVHD, 24 has also been used to prevent cardiac rejection. 25 We decided to use it after the second acute rejection to prevent both acute and chronic rejection without intensifying the immunosuppressive regimen.
Chronic renal failure is a wellknown compli cation of longterm immunosuppressive therapy after organ transplantation. The rapid decline in renal function during the year after transplanta tion prompted us to switch from tacrolimus to sirolimus, after which renal function improved.
Reports have not yet been published on two other face grafts that were performed in March 2006 in China and in January 2007 in France. More cases will be necessary to allow thorough study of the problems encountered in our patient. Meanwhile, the encouraging 18month outcomes of face transplantation in our patient suggest that this procedure can offer hope for some patients with severe disfigurement.
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